Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Teva
Queensland Health
Covington
Boehringer Ingelheim
Colorcon

Generated: September 18, 2019

34 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2019 - 2020

Loss of Exclusivity / End of Market Exclusivity Period dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "34 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2019 - 2020" DrugPatentWatch.com thinkBiotech, 2019 www.drugpatentwatch.com/p/nce-1/.
Media collateral
These NCE-1 dates indicate the first opportunity for generic drug companies to file Abbreviated New Drug Applications (ANDAs) for generic entry into branded drug markets. Generic launch is dependent on many factors, including FDA approval and patents. This information is provided as a rough estimate of generic application, and does not indicate when generics will launch. For more information see the complete DrugPatentWatch database.
LONSURF

Generic name: tipiracil hydrochloride; trifluridine
NCE-1 Date: September 2019

LONSURF is a drug marketed by Taiho Oncology. There are three patents protecting this drug.

This drug has seventy-two patent family members in thirty countries.

See drug price trends for LONSURF.

The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. There are two drug master file entries for this API. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.

RYZODEG 70/30

Generic name: insulin aspart; insulin degludec
NCE-1 Date: September 2019

RYZODEG 70/30 is a drug marketed by Novo. There are eighteen patents protecting this drug.

This drug has one hundred and eighty-six patent family members in twenty-three countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Additional details are available on the insulin aspart; insulin degludec profile page.

TRESIBA

Generic name: insulin degludec
NCE-1 Date: September 2019

Drug Price Trends for TRESIBA
TRESIBA is a drug marketed by Novo. There are seventeen patents protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-three countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Additional details are available on the insulin degludec profile page.

XULTOPHY 100/3.6

Generic name: insulin degludec; liraglutide
NCE-1 Date: September 2019

XULTOPHY 100/3.6 is a drug marketed by Novo. There are twenty patents protecting this drug.

This drug has two hundred and ninety-seven patent family members in twenty-seven countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Additional details are available on the insulin degludec; liraglutide profile page.

DESCOVY

Generic name: emtricitabine; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

Drug Price Trends for DESCOVY
DESCOVY is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.

This drug has three hundred and five patent family members in fifty-nine countries. There has been litigation on patents covering DESCOVY

See drug price trends for DESCOVY.

The generic ingredient in DESCOVY is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this API. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.

GENVOYA

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

GENVOYA is a drug marketed by Gilead Sciences Inc. There are thirteen patents protecting this drug.

This drug has six hundred and fifty patent family members in sixty countries. There has been litigation on patents covering GENVOYA

See drug price trends for GENVOYA.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this API. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

ODEFSEY

Generic name: emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

ODEFSEY is a drug marketed by Gilead Sciences Inc. There are eleven patents protecting this drug.

This drug has five hundred and twenty-two patent family members in sixty-one countries. There has been litigation on patents covering ODEFSEY

See drug price trends for ODEFSEY.

The generic ingredient in ODEFSEY is emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this API. Additional details are available on the emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate profile page.

SYMTUZA

Generic name: cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

Drug Price Trends for SYMTUZA
SYMTUZA is a drug marketed by Janssen Prods. There are thirteen patents protecting this drug.

This drug has six hundred and thirty-seven patent family members in fifty-nine countries. There has been litigation on patents covering SYMTUZA

See drug price trends for SYMTUZA.

The generic ingredient in SYMTUZA is cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this API. Additional details are available on the cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate profile page.

VEMLIDY

Generic name: tenofovir alafenamide fumarate
NCE-1 Date: November 2019

Drug Price Trends for VEMLIDY
VEMLIDY is a drug marketed by Gilead Sciences Inc. There are four patents protecting this drug.

This drug has one hundred and twenty-nine patent family members in forty-nine countries. There has been litigation on patents covering VEMLIDY

See drug price trends for VEMLIDY.

The generic ingredient in VEMLIDY is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this API. Additional details are available on the tenofovir alafenamide fumarate profile page.

EPCLUSA

Generic name: sofosbuvir; velpatasvir
NCE-1 Date: June 2020

Drug Price Trends for EPCLUSA
EPCLUSA is a drug marketed by Gilead Sciences Inc. There are fourteen patents protecting this drug.

This drug has four hundred and forty-five patent family members in forty-seven countries. There has been litigation on patents covering EPCLUSA

See drug price trends for EPCLUSA.

The generic ingredient in EPCLUSA is sofosbuvir; velpatasvir. There are nine drug master file entries for this API. Additional details are available on the sofosbuvir; velpatasvir profile page.

SMOFLIPID 20%

Generic name: fish oil; medium chain triglycerides; olive oil; soybean oil
NCE-1 Date: July 2020

SMOFLIPID 20% is a drug marketed by Fresenius Kabi Usa.

This drug has one hundred and two patent family members in twenty-one countries.

The generic ingredient in SMOFLIPID 20% is fish oil; medium chain triglycerides; olive oil; soybean oil. There are six drug master file entries for this API. Additional details are available on the fish oil; medium chain triglycerides; olive oil; soybean oil profile page.

SOLIQUA 100/33

Generic name: insulin glargine; lixisenatide
NCE-1 Date: July 2020

SOLIQUA 100/33 is a drug marketed by Sanofi-aventis Us. There are twenty-six patents protecting this drug.

This drug has four hundred and fifty-six patent family members in fifty countries. There has been litigation on patents covering SOLIQUA 100/33

The generic ingredient in SOLIQUA 100/33 is insulin glargine; lixisenatide. There are forty drug master file entries for this API. Additional details are available on the insulin glargine; lixisenatide profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Farmers Insurance
Merck
Federal Trade Commission
Medtronic
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.